argenx SE Sponsored ADR ARGX 深 滬
交易中 04-02 11:51:35 美东时间
746.31
+3.190
+0.43%
華盛通- 最 高759.89
- 今 開735.74
- 成交量 21.27万股
- 最 低 735.68
- 昨 收 743.12
- 總市值 463.18亿
- 52周最高 934.6199
- 市盈率 靜 38.02
- 換手率 0.34%
- 52周最低 510.055
- 委 比 -60.00%
- 總股本 6206.29万
- 歷史最高 934.6199
- 量 比 1.90
- 振 幅 3.26%
- 歷史最低 19.00
- 每 手 1
- 風險率 119.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Viridian Therapeutics Stock Falling Monday?
Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh in on elegrobart's market viability.
03-30 22:01
美股盘后 | 野村控股涨3.62%，argenx SE Sponsored ADR涨2.00%
野村控股涨3.62%；argenx SE Sponsored ADR涨2.00%；捷普科技涨2.00%
03-28 06:10
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 9.82%...
03-26 00:45
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Wedbush Reiterates Outperform on argenx, Maintains $1000 Price Target
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1000 price target.
03-09 20:38
argenx reports positive Phase 3 ADAPT OCULUS results for VYVGART in ocular myasthenia gravis
argenx reports positive Phase 3 ADAPT OCULUS results for VYVGART in ocular myasthenia gravis argenx SE announced it will present new clinical data at the 2026 American Academy of Neurology Annual Meeting (April 18-22, Chicago) on VYVGART (efgartigimod) in myasthenia gravis and chronic inflammatory d
03-06 14:00
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
Argenx SE (NASDAQ:ARGX) on Thursday reported upbeat fourth-quarter results and ...
02-27 21:48
Baird Maintains Neutral on argenx, Raises Price Target to $867
Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and raises the price target from $858 to $867.
02-27 20:31
argenx SE shares are trading lower. The company reported its Q4 financial results.
argenx SE shares are trading lower. The company reported its Q4 financial resul...
02-26 23:59
